thrombospondin type 1 domain containing 7BGenealiases: []
Q-omics provides the consensus-scored THSD7B profile across patient tissues and cancer cell-line models. THSD7B expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, THSD7B is differentially expressed in 9, with the highest sampling consensus in BLCA. Additionally, THSD7B RNA expression shows 20,485 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KIRP, BLCA, and LUAD as cancer lineages where THSD7B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for THSD7B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes THSD7B survival associations across molecular data types. THSD7B RNA expression shows survival associations in the most cancer types (25), followed by mutation status (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible THSD7B RNA expression–survival associations across cancer types. High THSD7B expression shows unfavorable associations in KIRP, READ and STAD, but favorable associations in KIRC, BRCA and LUAD. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for THSD7B RNA expression.
This table summarizes THSD7B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for THSD7B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. THSD7B shows lower tumor expression in BLCA, BRCA, KIRP, KIRC and PRAD and higher tumor expression in ESCA. The BLCA box plot shows higher THSD7B RNA expression in normal versus tumor tissue (log2 FC = −0.639, t-test p < 0.001).
This table shows molecular features associated with THSD7B in patient tissues and cancer cell lines. In patient samples, THSD7B shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, THSD7B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC.
